Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

Figure 11 Altered central nervous system responses in brain regions involved in rewards in obese subjects is reversed upon glucagon-like peptide 1 receptor activation. Central nervous system activity in regions involved in rewards processing show increased responses in obese subjects when exposed to food related images (Aii) associated with increased ad libitum food consumption when compared to healthy lean control (Ai). A response reversed upon administration of a GLP-1 analogue with concomitant reductions in ad libitum food intake (B), this effect antagonized by pre-treatment with GLP-1 antagonist Extendin 9-39 (EX9-39) (C). GLP-1: Glucagon-like peptide 1.